Mind the Curve: Dose–Response Fitting Biases the Synergy Scores across Software Used for Chemotherapy Combination Studies
Open Access
- 3 June 2023
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (11) , 9705
Abstract
Drug combinations are increasingly studied in the field of anticancer agents. Mathematical models, such as Loewe, Bliss, and HSA, are used to interpret drug combinations, while informatics tools help cancer researchers identify the most effective combinations. However, the different algorithms each software uses lead to results that do not always correlate. This study compared the performance of Combenefit (Ver. 2.021) and SynergyFinder (Ver. 3.6) in analyzing drug synergy by studying combinations involving non-steroidal analgesics (celecoxib and indomethacin) and antitumor drugs (carboplatin, gemcitabine, and vinorelbine) on two canine mammary tumor cell lines. The drugs were characterized, their optimal concentration–response ranges were determined, and nine concentrations of each drug were used to make combination matrices. Viability data were analyzed under the HSA, Loewe, and Bliss models. Celecoxib-based combinations showed the most consistent synergistic effect among software and reference models. Combination heatmaps revealed that Combenefit gave stronger synergy signals, while SynergyFinder produced better concentration–response fitting. When the average values of the combination matrices were compared, some combinations shifted from synergistic to antagonistic due to differences in the curve fitting. We also used a simulated dataset to normalize each software’s synergy scores, finding that Combenefit tends to increase the distance between synergistic and antagonistic combinations. We conclude that concentration–response data fitting biases the direction of the combination (synergistic or antagonistic). In contrast, the scoring from each software increases the differences among synergistic or antagonistic combinations in Combenefit when compared to SynergyFinder. We strongly recommend using multiple reference models and reporting complete data analysis for synergy claiming in combination studies.Keywords
Funding Information
- National Agency (1201378, 1201441)
- Development of Chile (ANID-Chile) (1201378, 1201441)
This publication has 23 references indexed in Scilit:
- BRAID: A Unifying Paradigm for the Analysis of Combined Drug ActionScientific Reports, 2016
- Combenefit: an interactive platform for the analysis and visualization of drug combinationsBioinformatics, 2016
- Analysis of drug combinations: current methodological landscapePharmacology Research & Perspectives, 2015
- Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay MethodCancer Research, 2010
- Systems biology and combination therapy in the quest for clinical efficacyNature Chemical Biology, 2006
- Effects of gemcitabine on cell proliferation and apoptosis in non-small-cell lung cancer (NSCLC) cell linesCancer Chemotherapy and Pharmacology, 2000
- Antiproliferative activity of vinorelbine (Navelbine) against six human melanoma cell linesJournal of Cancer Research and Clinical Oncology, 1992
- A three-dimensional model to analyze drug-drug interactionsAntiviral Research, 1990
- THE TOXICITY OF POISONS APPLIED JOINTLY1Annals of Applied Biology, 1939
- Über KombinationswirkungenNaunyn-Schmiedeberg's Archives of Pharmacology, 1926